Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Should you get an RSV vaccine this fall? What to know and where to get a shot - 2Instructions to Perceive and Grasp the Early Side effects of Cellular breakdown in the lungs
- 3A Russian fighting for Ukraine conned the Kremlin out of $500,000 by faking his own death
- 4The most effective method to Remain Ahead in the Most recent Advanced Patterns with a Web based Advertising Degree
- 5NASA study shows how satellite 'light pollution' hinders space telescopes
- Dominating Capable Mastercard Utilization: Key Contemplations
- Anthony Joshua's driver charged over Nigeria crash that killed two
- What are parents to do as doctors clash with Trump administration over vaccines?
- Figure out How to Acquire Rewarding Open Record Rewards
- Flu season is ramping up, and some experts are "pretty worried"
- Family Matters: Tips and Guidance for Effective Nurturing and Everyday Life
- Figure out How to Put resources into Lab Precious stones
- Setbacks in Texas and elsewhere put Republicans' redistricting hopes in doubt as key deadlines loom
- Photos of amputees in Gaza, struggling to survive after losing limbs to Israeli airstrikes
